Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial

Circulation

Volumn 107, Issue 21, 2003, Pages 2690-2696

  Gheorghiade, Mihai ^a   Niazi, Imran ^b   Ouyang, John ^c   Czerwiec, Frank ^c   Kambayashi, Jun ichi ^c   Zampino, Manuela ^a   Orlandi, Cesare ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Wisconsin Ctr for Clinical Research   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Edema; Heart failure; Hormones; Trials

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDRALAZINE; NITRATE; PLACEBO; POTASSIUM; SODIUM; TOLVAPTAN; VASOPRESSIN V2 RECEPTOR; ARGIPRESSIN; BENZAZEPINE DERIVATIVE; DIURETIC AGENT; VASOPRESSIN RECEPTOR;

ADULT; AGED; ARTICLE; ASTHENIA; ASTHMA; BLOOD PRESSURE; BODY WEIGHT; CELLULITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEMALE; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPONATREMIA; KIDNEY FUNCTION; LEG CRAMP; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; POLYURIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SUPRAVENTRICULAR TACHYCARDIA; THIRST; TREATMENT OUTCOME; URINE VOLUME; VERTIGO; WEIGHT REDUCTION; XEROSTOMIA; BLOOD; CHRONIC DISEASE; DRUG ANTAGONISM; ELECTROLYTE BALANCE; HEART EDEMA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OSMOLARITY; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ARGININE VASOPRESSIN; BENZAZEPINES; BODY WEIGHT; CHRONIC DISEASE; DIURETICS; DOUBLE-BLIND METHOD; EDEMA, CARDIAC; FEMALE; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RECEPTORS, VASOPRESSIN; SODIUM; TREATMENT OUTCOME; URINALYSIS; WATER-ELECTROLYTE BALANCE;

EID: 0037904417     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.0000070422.41439.04     Document Type: Article

References (13)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association: 2002.
2. Bennett SJ, Huster GA, Baker SL, et al. Characterization of the precipitants of hospitalization for heart failure decompensation. Am J Crit Care. 1998:7:168-174.
3. Goldsmith SR. Vasopressin. a therapeutic target in congestive heart failure? J Card Fail. 1999;5:347-356.
4. Kubo SH, Clark M, Laragh JH, et al. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol. 1987;60:1322-1328.
5. Ikram H, Chan W, Espiner EA, et al. Hemodynamic and hormone response to acute and chronic furosemide therapy in congestive heart failure. Clin Sci. 1980:69:443-447.
6. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311-1315.
7. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and risk of primary cardiac arrest. N Engl J Med. 1994;330:1852-1857.
8. Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1985;55:1-15.
9. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867.
10. Hirano T, Yamamura Y, Nakamura S, et al. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmocol Exp Ther. 2000;292:288-294.
11. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547.
12. Kearney MT, Fox KAA, Lee AJ, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40:1801-1808.
13. Goldsmith SR, Francis GS, Cowley AW Jr, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Ccirdiol. 1983;1:1385-1390.